DiaMedica Therapeutics Inc
DiaMedica Therapeutics develops DM199, a recombinant KLK1 protein for acute ischemic stroke, preeclampsia, and fetal growth restriction.
10-QAug 10Latest SEC filing, period to Jun 30
Aug 10Latest story
August 2026
Sign inSign inDiaMedica Therapeutics develops DM199, a recombinant KLK1 protein for acute ischemic stroke, preeclampsia, and fetal growth restriction.